Pro Dex earnings release, September 3, 2026

Pro Dex Inc (PDEX) · Form 8-K, Item 2.02 · Filed · SEC filing

Contact: Richard L. Van Kirk,

Chief Executive Officer

(949) 769-3200

For Immediate Release

PRO-DEX, INC. ANNOUNCES FISCAL 2026

FOURTH QUARTER AND FULL-YEAR RESULTS

IRVINE,

CA,

September 3, 2026 - PRO-DEX, INC. (NasdaqCM: PDEX) t oday announced financial results for its fiscal 2026 fourth quarter and full-year ended June 30, 2026.

Quarter Ended June 30, 2026

Net sales for the three months ended June 30, 2026 increased $2.9 million, or 17%, to $20.4 million from $17.5 million for the three months ended June 30, 2025, due primarily to increased revenue from our largest customer’s next generation orthopedic handpiece. Gross profit for the three months ended June 30, 2026 increased $3.6 million, or 103%, to $7.1 million from $3.5 million for the three months ended June 30, 2025 similarly attributable to increased revenue from our largest customer’s next generation handpiece. During much of the fourth quarter of fiscal 2025, we were shipping our largest customer its legacy handpiece, until the customer released its product hold on the next generation handpiece late in that quarter, at which point we resumed production and shipment of its next generation handpiece late in the same quarter. Our gross margin increased from 20% for the three months ended

June 30, 2025, to 35% for the three months ended June 30, 2026, due to favorable product mix, better absorption of our indirect manufacturing costs and favorable margins derived from our subsidiary, Advanced Precision Machining, LLC (“APM”), which we acquired in the third quarter of fiscal 2026.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2026, increased $1.4 million to $3.6 million, compared to $2.2 million for the prior fiscal year’s corresponding quarter. Selling, general and administrative expenses increased by $1.3 million, and research and development expenses increased by $111,000 for the quarter ended June 30, 2026, compared to the corresponding quarter in fiscal 2025. The increases relate primarily to a $349,000 allowance for uncollectible receivables, $436,000 of APM’s separate administrative expenses, $250,000 in consulting payments paid to the founder of APM to assist with our manufacturing operations, as well as increased personnel and related expenses to support our continued growth.

Our operating income for the quarter ended June 30, 2026, increased $2.2 million, or 163%, to $3.5 million compared to $1.3 million for the prior fiscal year’s corresponding quarter. The increase reflects our increased gross profit partially offset by higher operating expenses, as described above.

Net income for the quarter ended June 30, 2026, increased by $1.7 million to $2.9 million, or $0.87 per diluted share, compared to $1.2 million, or $0.36 per diluted share, in the corresponding quarter in 2025.

Year Ended June 30, 2026

Net sales for the fiscal year ended June 30, 2026 increased $10.9 million, or 16%, to $77.5 million from $66.6 million for the fiscal year ended June 30, 2025, due primarily to a of $15.3 million increase in revenue from our largest customer, related primarily to its next generation orthopedic handpiece, offset by a $6.0 million reduction in repair revenue, primarily from our largest customer. Additionally, our NRE revenue increased $952,000 in the fiscal year ended June 30, 2026 compared to the prior fiscal year and APM added $718,000 in revenue since our acquistion of APM on February 9, 2026.

Gross profit for the fiscal year ended June 30, 2026, increased $4.8 million, or 25%, to $24.3 million compared to $19.5 million for fiscal 2025. Our gross margin increased from 29% in fiscal

2025 to 31% in fiscal 2026, due to overall favorable product mix.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2026, increased

$2.5 million or 29% to $11.3 million from $8.8 million in the prior fiscal year. The increase relates primarily to an increase of $1.2 million in personnel costs included in general and administrative expenses to support our continued growth, which amount includes $582,000 of company-wide bonus accruals and non-cash equity compensation expense, as well as $500,000 in non-recurring consulting fees paid to

APM’s founder, $669,000 of APM’s separate operating expenses, and the $349,000 allowance for uncollectible receivables referenced above. The decrease in research and development expenses in fiscal 2026 is primarily related to a decrease in legal expenses related to intellectual property matters.

Our operating income for the year ended June 30, 2026, increased $2.3 million, or 22%, to $13.0 million compared to $10.7 million for the prior fiscal year’s corresponding quarter. The increase reflects our increased sales and gross profit, as described above.

Net income for the fiscal year ended June 30, 2026, was $13.7 million, or $4.12 per diluted share, compared to $9.0 million, or $2.67 per diluted share, for fiscal

2025. Our net income for the fiscal years ended June 30, 2026 and 2025 contains gains on our marketable equity investments of $5.7 million and $2.1 million, respectively. All of our investments are recorded at estimated fair value, and the valuation can be highly volatile.

CEO Comments

“We are very pleased with our fiscal 2026 performance including completing the acquisition of APM and increasing sales by 16%.” said the Company’s

President and Chief Executive Officer Richard L. (“Rick”) Van Kirk. “I continue to extend my gratitude to the Pro-Dex team for their continued teamwork and focus on execution.” Mr. Van Kirk concluded.

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting software and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality, and regulatory consulting services to our customers. Our APM subsidiary manufactures parts and assemblies for the aerospace and defense industries in addition to providing several machined components to support Pro-Dex’s customers. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries; however, these air motors comprise a de minimis portion of our business. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's websites at www.pro-dex.com and www.advanced-precision.com.

Financial statements

Income Statement

Years Ended June 30, — (In thousands, except per share data)

Three Months Ended June 30, (Unaudited) – 2026Three Months Ended June 30, (Unaudited) – 2025Years Ended June 30, – 2026Years Ended June 30, – 2025
Net sales20,40517,49477,54866,593
Cost of sales13,31414,00453,21347,083
Gross profit7,0913,49024,33519,510
Operating expenses:Selling, general and administrative expenses2,5461,2417,9995,185
Operating expenses:Research and development costs1,0169053,3453,636
Operating expenses:Total operating expenses3,5622,14611,3448,821
Operating expenses:Operating income3,5291,34412,99110,689
Operating expenses:Interest expense-271-226-812-829
Operating expenses:Gain on marketable equity investments, net2124605,6552,116
Operating expenses:Interest and dividend income552118182
Operating expenses:Income before income taxes3,5251,59918,01512,058
Operating expenses:Income tax expense6684034,3533,080
Operating expenses:Net income2,8571,19613,6628,978
Basic & Diluted income per share:Basic net income per share0.90.374.242.73
Basic & Diluted income per share:Diluted net income per share0.870.364.122.67
Weighted average shares outstanding:Basic3,189,7273,261,0433,225,8843,287,844
Weighted average shares outstanding:Diluted3,294,3253,350,4493,317,0643,361,207

Balance Sheet

(In thousands, except share data)

June 30, – 2026June 30, – 2025
Current assets:Cash and cash equivalents8,192419
Current assets:Investments1,1506,740
Current assets:Accounts receivable, net of allowance for credit losses of $349 and $0 at June 30, 2026 and 2025, respectively21,20516,433
Current assets:Deferred costs7024
Current assets:Inventory21,45822,213
Current assets:Income taxes receivable6201,056
Current assets:Prepaid expenses553410
Current assets:Total current assets53,24847,295
Current assets:Land and building, net5,9676,061
Current assets:Equipment and improvements, net5,3735,153
Current assets:Right of use asset, net6021,050
Current assets:Intangibles, net68626
Current assets:Deferred income taxes, net1,5441,415
Current assets:Investments504148
Current assets:Goodwill6,525
Current assets:Other assets6044
Current assets:Total assets74,50961,192
Current liabilities:Accounts payable4,2624,614
Current liabilities:Accrued liabilities4,3663,479
Current liabilities:Income taxes payable124186
Current liabilities:Deferred revenue26202
Current liabilities:Notes payable4,2056,148
Current liabilities:Total current liabilities12,98314,629
Non-current liabilities:Lease liability, net of current portion627685
Non-current liabilities:Notes payable, net of current portion13,2669,246
Non-current liabilities:Total non-current liabilities13,8939,931
Non-current liabilities:Total liabilities26,87624,560
Shareholders’ equity:Common stock, no par value, 50,000,000 shares authorized; 3,186,135 and 3,261,043 shares issued and outstanding at June 30, 2026 and 2025, respectively704
Shareholders’ equity:Retained earnings47,63335,928
Shareholders’ equity:Total shareholders’ equity47,63336,632
Shareholders’ equity:Total liabilities and shareholders’ equity74,50961,192

Cash Flow

Years Ended June 30, — (In thousands) (in thousands)

Years Ended June 30, – 2026Years Ended June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income13,6628,978
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Depreciation and amortization1,3941,239
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Unrealized loss (gain) on equity investments3,434-1,521
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Gain on sale of investments-9,089-595
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Non-cash straight-line lease amortization-49-33
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Allowance for credit losses368
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Amortization of loan fees, net129
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Share-based compensation688555
Adjustments to reconcile net income to net cash provided by (used in) operating activities:Deferred income taxes-129140
Changes in operating assets and liabilities:Accounts receivable-4,713-2,546
Changes in operating assets and liabilities:Deferred costs-46238
Changes in operating assets and liabilities:Inventory1,630-6,944
Changes in operating assets and liabilities:Prepaid expenses and other assets-105-67
Changes in operating assets and liabilities:Accounts payable and accrued expenses-12179
Changes in operating assets and liabilities:Deferred revenue-176188
Changes in operating assets and liabilities:Income taxes373-1,502
Changes in operating assets and liabilities:Net cash provided by (used in) operating activities7,242-1,682
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of equipment and improvements-483-1,246
CASH FLOWS FROM INVESTING ACTIVITIES:Purchase of APM, net of cash acquired-6,493
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of investments-350-899
CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from sale of investments11,2391,907
Full release

Statements herein concerning the Company's plans, growth and strategies may include “forward-looking statements” within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business risks of the Company set forth in the Company's filings with the Securities and Exchange Commission, including is Annual Report of Form 10-K. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

(tables follow)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Pro Dex earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.